
Soligenix SNGX
$ 1.08
-10.74%
Quarterly report 2025-Q3
added 11-07-2025
Soligenix Interest Expense 2011-2026 | SNGX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Soligenix
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.2 K | 5.92 K | 30.8 K | 61.1 K | 149 K | - | - | 2.22 K | -8.02 K | 1.31 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 149 K | -8.02 K | 35.7 K |
Quarterly Interest Expense Soligenix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.82 K | -7.92 K | -788 | - | 67 K | 64.2 K | 173 K | - | - | 2.35 K | 40.9 K | - | - | - | -146 K | - | 30.8 K | -215 K | -129 K | - | 486 | 2.02 K | 21.9 K | - | - | - | - | - | - | - | - | - | -789 | 5.23 K | 4.75 K | - | 391 K | 1.26 K | -3.88 K | - | -3.73 K | 551 | 561 | - | 428 | 322 | 291 | - | 652 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 391 K | -215 K | 10.6 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
131 B | $ 18.06 | - | $ 28.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 19.44 | -0.46 % | $ 909 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | ||
|
Protara Therapeutics
TARA
|
34 K | $ 5.03 | -3.08 % | $ 215 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Tarsus Pharmaceuticals
TARS
|
-202 K | $ 67.0 | -0.3 % | $ 2.8 B | ||
|
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | ||
|
Theravance Biopharma
TBPH
|
10.2 M | $ 14.9 | -1.91 % | $ 750 M | ||
|
Avid Bioservices
CDMO
|
4.34 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.2 | -6.97 % | $ 306 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
Bio-Techne Corporation
TECH
|
831 K | $ 51.31 | -2.65 % | $ 8.08 B | ||
|
Tenax Therapeutics
TENX
|
23 K | $ 14.64 | -2.2 % | $ 574 M | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
3.59 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
874 K | $ 1.07 | -2.29 % | $ 21.9 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
916 M | $ 28.76 | -3.43 % | $ 32.9 B | ||
|
Enochian Biosciences
ENOB
|
122 K | - | - | $ 40.5 M | ||
|
Equillium
EQ
|
-76 K | $ 2.03 | -1.46 % | $ 116 M | ||
|
Eton Pharmaceuticals
ETON
|
955 K | $ 23.81 | 1.51 % | $ 641 M | ||
|
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 46.38 | -2.45 % | $ 4.17 B |